Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS

Xu, Pengfei; Yin, Qi; Shen, Jiajia; Chen, Lingli; Zhang, Zhiwen

doi:10.1016/j.ijpharm.2013.06.053

Cited by 108 publications

(51 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, emulsomes incorporated up to 18.83 % SIL. This higher loading capacity relates to their multilamellarity and represents a considerable advantage over SLNs (Li et al 2006;Zhang et al 2007;Lian et al 2013;Xu et al 2013;Ucisik et al 2015).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, it has a short half-life Bonepally et al 2013). To overcome these shortcomings, several alternative preparations of SIL have been tested, including SIL b-cyclodextrin inclusion complexes (Arcan and Brambilla 1992), SIL-phospholipid complexes (Xiao et al 2006), an SIL-nanosuspension (Zheng et al 2011), a super-saturable self-emulsifying drug delivery system (Wei et al 2012), an SIL-nanodispersion (Cui et al 2013), porous silica nanoparticles (Cao et al 2013), phyto-liposomes (Angelico et al 2014), and solid lipid nanoparticles Xu et al 2013). However, these formulations are degraded rapidly by stomach acids or intestinal enzymes and bile salts if taken orally.…”

Section: Introductionmentioning

confidence: 99%

“…They have been proposed as alternative SIL delivery systems by many researchers. However, their loading capacities for SIL were 2.13, 3.00, 4.17, and 7.55 %, respectively (Li et al 2006;Zhang et al 2007;Lian et al 2013;Xu et al 2013;). Emulsomes differ from SLNs because they are surrounded by phospholipid layers (Paliwal et al 2009;Giovanna et al 2015;Ucisik et al 2015).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Preparation and performance evaluation of emulsomes as a drug delivery system for silybin

Zhou

Chen

2015

Arch. Pharm. Res.

View full text Add to dashboard Cite

We developed silybin (SIL) emulsomes and evaluated their physicochemical properties and the in vivo pharmacokinetics of SIL delivered by emulsomes in rats. SIL emulsomes were prepared using the thin film dispersion method. SIL emulsomes were evaluated for their entrapment efficiency, particle size, zeta potential, morphology, in vitro release, and in vivo drug delivery in rats. The entrapment efficiency was above 80 %. The average particle size and zeta potential were 364.1 ± 20 nm and -34 ± 8 mV, respectively. Morphological analysis revealed that the SIL emulsomes were spherical in shape. Compared to an SIL solution, emulsomes produced sustained release of SIL for up to 48 h after an initial burst release in vitro. The pharmacokinetics of SIL emulsomes in rats were evaluated after intravenous injection, and the results were compared with those obtained for the control SIL solution. Following SIL delivery by emulsomes, the area under the curve was 2.2-fold higher and the mean residence time was 2.5-fold higher than the corresponding values recorded using SIL solution. Hence, emulsomes might represent a promising system for improving the bioavailability of lipophilic drugs. Moreover, emulsomes produce sustained drug release, which is advantageous in the clinical setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Preparation and performance evaluation of emulsomes as a drug delivery system for silybin

Zhou

Chen

2015

Arch. Pharm. Res.

View full text Add to dashboard Cite

show abstract

“…In order to invade and enter the blood circulation, tumor cells require matrix metalloproteinases (MMPs) especially MMP-2 and MMP-9 to degrade the surrounding ECM components and nanoformulations that target these MMPs have inhibited tumor cell invasion and migration (Meng et al, 2012;Kojima et al, 2013;Xu et al, 2013). Gadolinium metallo-fullerenol nanoparticles (f-NPs) down regulated mRNA expression of both MMP-2 (∼40 %) and MMP-9…”

Section: Invasion Inhibition Strategiesmentioning

confidence: 99%

Development of nanotheranostics against metastatic breast cancer — A focus on the biology & mechanistic approaches

Subramanian

Manigandan

Sivashankari

et al. 2015

Biotechnology Advances

View full text Add to dashboard Cite

“…In addition, VRS exhibited a short half-life of 40 min following intravenous (IV) administration, compared with $2 h following oral administration and underwent extensive first-pass metabolism (Tran et al, 2014). In the effort, to overcome these problems, lipid nanoparticles can be an ideal system for enhancement of in vitro as well as in vivo drug performance, especially hydrophobic anticancer drug (Aznar et al, 2013;Minelli et al, 2013;Xu et al, 2013;Kumar et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Development of lipid nanoparticles for a histone deacetylases inhibitor as a promising anticancer therapeutic

et al. 2014

View full text Add to dashboard Cite

Background: Vorinostat (VRS), a histone deacetylases inhibitor, has significant cytotoxic potential in a large number of human cancer cell lines. Objective: To clarify its promising anticancer potential and to improve its drawback related to physical properties and in vivo performance of VRS. Methods: VRS was successfully incorporated into nanostructured lipid carriers (NLCs) by the hot microemulsion method using sonication following a homogenization technique. Results: After the optimization process, VRS-loaded NLCs (VRS-NLCs) were obtained as ideal quality nanoparticles with a spherical shape, small size ($150 nm), negative charge ($À22 mV), and narrow size distribution. In addition, the high entrapment efficiency ($99%) and sustained drug release profile were recorded. Cytotoxicity study in three different cell lines (A549, MCF-7, and SCC-7) demonstrated higher cytotoxicity of VRS-NLCs than free drug. Finally, the AUC of VRS (118.16 ± 17.35 mgh/mL) was enhanced $4.4 times compared with that of free drug (27.03 ± 3.25 mgh/mL). Conclusion: These results suggest the potential of NLCs as an oral delivery system for enhancement of cellular uptake, in vitro cytotoxicity in cancer cell lines and the oral bioavailability of VRS.

show abstract

Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS

Cited by 108 publications

References 46 publications

Preparation and performance evaluation of emulsomes as a drug delivery system for silybin

Preparation and performance evaluation of emulsomes as a drug delivery system for silybin

Development of nanotheranostics against metastatic breast cancer — A focus on the biology & mechanistic approaches

Development of lipid nanoparticles for a histone deacetylases inhibitor as a promising anticancer therapeutic

Contact Info

Product

Resources

About